HKU Scholars Hub: Browsing DSpace

Browsing by Author Yen, CJ

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 8 of 8

	Title	Author(s)	Issue Date	Views
	A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma Journal:Clinical Cancer Research	Yau, TCC Lencioni, R Sukeepaisarnjaroen, W Chao, Y Yen, CJ Lausoontornsiri, W Chen, PJ Sanpajit, T Camp, A Cox, DS Gagnon, R Liu, Y Raffensperger, KE Kulkarni, D Kallender, H Ottesen, LH Poon, RTP Bottaro, DP	2016	53
	A phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology	Yau, TCC Sukeepaisarnjaroen, W Chao, Y Yen, CJ Lausoontornsiri, W Chen, PJ Sanpajit, T Lencioni, R Camp, AC Cox, DS Kallender, H Ottesen, LH Poon, RTP	2012	124
	A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Hepatology	Yau, T Yen, CJ Chen, PJ Chau, Y Lencioni, R Kallender, H Ottesen, LH Poon, RTP	2011	120
	A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology	Yau, TCC Sukeepaisarnjaroen, W Chao, Y Yen, CJ Lausoontornsiri, W Chen, PJ Sanpajit, T Lencioni, R Camp, AC Cox, DS Kallender, H Ottesen, LH Poon, RTP	2012	133
	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Journal:Clinical Cancer Research	Lim, HY Merle, P Weiss, KH Yau, TCC Ross, P Mazzaferro, V Blanc, JF Ma, YT Yen, CJ Kocsis, J Choo, SP Sukeepaisarnjaroen, W Gérolami, R Dufour, JF Gane, EJ Ryoo, BY Peck-Radosavljevic, M Dao, T Yeo, W Lamlertthon, W Thongsawat, S Teufel, M Roth, K Reis, D Childs, BH Krissel, H Llovet, JM	2018	18
	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study Journal:European Journal of Cancer	Chau, I Peck-Radosavljevic, M Borg, C Malfertheiner, P Seitz, JF Park, JO Ryoo, BY Yen, CJ Kudo, M Poon, RTP Pastorelli, D Blanc, JF Chung, HC Baron, AD Okusaka, T Bowman, L Cui, ZL Girvan, AC Abada, PB Yang, L Zhu, AX	2017	23
	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial Journal:The Lancet Oncology	Zhu, AX Park, JO Ryoo, BY Yen, CJ Poon, RTP	2015	61
	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma Journal:Journal of Hepatology	Abou-Alfa, GK Puig, O Daniele, B Kudo, M Merle, P Park, JW Ross, P Peron, JM Ebert, O Chan, S Poon, RTP Colombo, M Okusaka, T Ryoo, BY Minguez, B Tanaka, T Ohtomo, T Ukrainskyj, S Boisserie, F Rutman, O Chen, YC Xu, C Shochat, E Jukofsky, L Reis, B Chen, G Di Laurenzio, L Lee, R Yen, CJ	2016	51

Showing results 1 to 8 of 8